US 20060122147A1

(19) **United States**

(12) **Patent Application Publication** (10) **Pub. No.: US 2006/0122147 A1**

Wohlrab (43) **Pub. Date: Jun. 8, 2006**

(54) **COMBINATION PREPARATION OF HYALURONIC ACID AND AT LEAST OE LOCAL ANESTHETIC AND THE USE THEREOF**

(76) Inventor: **David Wohlrab**, Halle (DE)

Correspondence Address:
LEYDIG VOIT & MAYER, LTD
TWO PRUDENTIAL PLAZA, SUITE 4900
180 NORTH STETSON AVENUE
CHICAGO, IL 60601-6780 (US)

(21) Appl. No.: **10/529,924**

(22) PCT Filed: **Sep. 9, 2003**

(86) PCT No.: **PCT/EP03/10822**

(30) **Foreign Application Priority Data**

Oct. 4, 2002 (DE)..... 102 46 340.9

Publication Classification

(51) **Int. Cl.**
A61K 31/728 (2006.01)
C08B 37/00 (2006.01)

(52) **U.S. Cl.** **514/54**; 536/53

(57) **ABSTRACT**

The invention relates to a combination preparation comprising an active agent A from the group hyaluronic acid, the salts and fragments thereof, at least one active agent B from the group of local anaesthetics and derivatives thereof and also if necessary further additives. These combination preparations are used for the medical treatment of degenerative and traumatic diseases of all joints, for the treatment of articular cartilage and cartilage bone defects and also meniscus and intervertebral disc lesions, such as e.g. arthrosis, articular rheumatism, osteochondritis dissecans, flake fractures, meniscus lesions and for the treatment of skin and mucous membrane changes, also from cosmetic aspects.

Figure 1



Figure 2



COMBINATION PREPARATION OF HYALURONIC ACID AND AT LEAST OE LOCAL ANESTHETIC AND THE USE THEREOF

[0001] The invention relates to a combination preparation comprising an active agent A from the group hyaluronic acid, the salts and fragments thereof, at least one active substance B from the group of local anaesthetics and derivatives thereof and also if necessary further additives. These combination preparations are used for the medical treatment of degenerative and traumatic diseases of all joints, for the treatment of articular cartilage and cartilage bone defects and also meniscus and intervertebral disc lesions, such as e.g. arthrosis, articular rheumatism, osteochondritis dissecans, flake fractures, meniscus lesions and for the treatment of skin and mucous membrane changes, also from cosmetic aspects.

[0002] The chemical name for hyaluronic acid is hyaluronan. Its chemical structure corresponds to the formula



[0003] Despite the positive clinical experiences with high molecular hyaluronic acid and the salts thereof (mol mass >1×106 Dalton), knowledge about the operating mechanism is incomplete. The present state of knowledge identifies intraarticularly applied hyaluronic acid as a lubricant (A. Lussier et al. (1996); J. Rheumatol. 23, 1579-1585; D. Scale et al. (1994); Current Therapeutic Research. 55, 220-232; M. Wobig et al. (1998) Clinical Therapeutics. 20, 410-423). Furthermore, it was indicated that hyaluronic acid has intraarticularly anti-inflammatory properties (K. W. Marshall (1997) Today's Therapeutic Trends. 15, 99-108; K. W. Marshall (2000) Curr. Opin. Rheumatol. 12, 468-474).

[0004] Arthrosis begins with initial damage of the cartilage tissue because of various causes. This results in reactive synovialitis which for its part causes both pathological changes in the synovial fluid, i.e. reduction in concentration and molecular weight of the hyaluronic acid, and also the release of inflammation mediators. This leads to secondary cartilage damage and hence finally to arthrosis which, in addition to cartilage tissue, affects all other articular structures (J. P. Pelletier et al. (1993) J. Rheumatol. 20, 19-24).

[0005] It is known that intraarticularly applied hyaluronic acid leads to improvement in joint mobility, to pain reduction, to inhibition of inflammation processes and, under in vitro conditions, to the increase of chondrocyte proliferation

[0006] Starting herefrom, it was the object of the present invention to provide a combination preparation which can be applied in various forms and in the case of which the active substances can be released in a specifically delayed manner.

[0007] This object is achieved by the combination preparation with the features of claim **1**. The use of the combination preparation is described in claim **15**. The further dependent claims demonstrate advantageous developments.

[0008] According to the invention, a combination preparation consisting of an active agent A from the group hyaluronic acid, the physiological salts and fragments thereof, at least one active agent B from the group of local anaesthetics and derivatives thereof and also if necessary further additives is provided.

[0009] It was established that, due to the considerable molecular size of hyaluronic acid (1-6×10^6 Da), this must be split several times before it can leave the intraarticular space and be decomposed or incorporated in cartilage tissue. These splitting processes take hours up to several days dependent upon the mol mass of the hyaluronic acid.

[0010] Because of this extended intraarticular dwell time, in comparison to other low molecular substances, such as e.g. local anaesthetics, high molecular hyaluronic acid, the salts or the fragments thereof are suitable as carriers for substances which, without bonding of this type to a carrier molecule, have a significantly shortened intraarticular dwell time and hence a very short period of activity.

[0011] All the formulations known from the state of the art are possible as galenic formulation. Included herein are in particular intraarticularly, intradiscally, subcutaneously, intracutaneously or topically applicable galenic formulations.

[0012] Preferably, compounds chosen as active agent A are compounds from the group hyaluronic acid, the salts and fragments thereof and, as active agent B, compounds from the group of local anaesthetics and derivatives thereof, which compounds have together a chemical or physical bond, the active substance B being able to be released in a delayed manner. The pH value of the formulation thereby makes possible an optimum bond between the two active agents and the release of the active agent B can be controlled via alteration in the pH value of the surrounding medium.

[0013] Preferably, the active agent A is contained in the

weight. The active agent B is preferably in a concentration between 0.001 and 20% by weight, preferably between 0.001 and 5.0% by weight.

[0014] Furthermore, further additives can be contained in the combination preparation. There are included herein for example agents with radical interceptor properties, in particular tocopherol derivatives or ascorbic acid derivatives. Furthermore, agents of the hyaline cartilage tissue can be used, in particular glucosamine sulphate derivatives or chondroitin sulphate derivatives. Furthermore, agents with a steroidal and corticoidal effect can be used, in particular glucocorticoids. There are possible as additives furthermore non-steroidal antiphlogistics which are described also as antirheumatics, in particular indometacin, diclofenac or salicylic acid derivatives and analgesics, in particular oxicams, aniline or anthranilic acid derivatives. The combination preparation can have as additive likewise substances with an inhibitory effect on prostaglandin synthesis, in particular lipoxygenase inhibitors, cyclo-oxygenase inhibitors and phospholipase A2 inhibitors. Likewise, there are possible as additives growth factors, in particulars retinol or bone morphogenetic proteins (BMPs), vitamins, in particular vitamin A, C, B12 or biotin, antioxidants, in particular flavonoids or glutathione, and agents with water-binding properties, in particular urea or arginine.

[0015] The combination preparation can be produced as any galenic formulation, e.g. as a solution, suspension, emulsion, paste, ointment, gel, cream, lotion, varnish, powder, soap, surfactant-containing cleaning preparation, oil, lipstick, lip salve, mascara, eye liner, eye shadow, rouge, powder, emulsion or wax makeup, sun protection, pre-sun and after-sun preparations or as a spray.

[0016] The application of the combination preparation can be effected both on humans and on animals. The combination preparations according to the invention can be applied both in human and veterinary medicine and in cosmetics.

[0017] The application fields of the combination preparations relate to human and veterinary medical therapy, prophylaxis and/or metaphylaxis of degenerative or traumatic articular diseases and articular function disorders, articular cartilage and cartilage bone defects, meniscus and intervertebral disc diseases. There are included herein for example the increase in chondrocyte proliferation, the stabilisation and/or regeneration of articular structures, in particular of the articular cartilage and menisci, the increase in joint mobility and the inhibition of inflammatory processes.

[0018] Likewise, the combination preparation can however by used also for treating skin and mucous membrane changes both from medical and cosmetic viewpoints.

[0019] According to the invention, also the use of at least one active agent from the group hyaluronic acid, the salts and fragments thereof in combination with at least one active agent B from the group of local anaesthetics and derivatives thereof for preparing a medicament for human and veterinary medical therapy, prophylaxis and/or metaphylaxis of articular diseases and articular function disorders is provided.

[0020] The invention is intended to be explained with

EXAMPLE 1

Physiological Compatibility of the Galenic Formulations According to the Invention

Production:

[0021] Lidocaine hydrochloride (University pharmacy of the Martin Luther University Halle-Wittenberg) and hyaluronic acid (Aqua Biochem, Dessau) (MG 1.5×10^6 Da) were present primarily in powder form. In order to produce 2% parent solutions, corresponding quantities were dissolved in RPMI medium (Seromed, Berlin) and subsequently filtered in a sterile manner. In order to produce a lidocaine-hyaluronic acid mixture, these parent solutions were mixed in equal parts. The substance addition to the cell culture was effected on the 10^{th} culture day with medium change. Corresponding quantities of the test substances (parent solutions) were added here so that a respective end concentration of 5×10^{-5} mmol/1 was achieved.

Preparation of the Biological Material:

[0022] The tests were effected on human chondrocytes which were isolated from arthrotically changed knee joint cartilage. The cartilage tissue stemmed from femoral articular surfaces resected during implantation of total knee endoprostheses. Exclusively arthrotically changed cartilage tissue from three different donors without known relevant secondary diseases, in particular without rheumatoid arthritis, was used.

[0023] The intraoperatively obtained bone-cartilage fragments were transferred firstly into sterile L15 medium (Seromed, Berlin) as transport medium. Subsequently, the separation of the cartilage tissue from the subchondral bone was effected under sterile conditions by means of a scalpel and also sharp severance of the tissue into pieces of approximately 1 mm^3. The enzymatic isolation of the chondrocytes from the pieces of cartilage was effected by means of pronase and collagenase A (Boehringer Mannheim) over a timespan of 16 hours.

Test Conditions:

[0024] The isolated chondrocytes were cultivated in 24 well plates in RPMI medium (Seromed, Berlin) with the addition of various antibiotics at 37° C. and 5% carbon dioxide in an incubator as a monolayer culture. The medium change was effected every 2 days. After 10 culture days, finally a medium change was effected and hereby the addition of the respective test substances which were dissolved in the culture medium. In addition, an untreated chondrocyte population respectively was run jointly as control.

Implementation of the Test:

[0025] The measurement of the ^3H thymidine incorporation as a measure of the DNA synthesis yield was effected 24, 48 or 72 hours after addition of the substance. At the end of the culture time, 20 µl ^3H-methylthymidine (specific activity 60.3 Ci/mmol; American Radiolabeled Chemicals Inc., St. Louis, USA) was added per well to the cell culture. Two hours after the addition of the ^3H thymidine, the medium was suctioned out of the chambers by means of a Cell Harvester (Berthold GmbH, Bad Wildbad). Each culture chamber was supplied with 200 µl trypsine and the cell

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.